
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings is a solid investment opportunity due to its diverse portfolio in the regenerative medicine market. While challenges in the Advanced Wound Care market may affect the stock in the short term, ORGO's strong cash balance and potential for growth make it a reliable long-term investment. Additionally, the company's focus on minimal market disruption and strong product portfolio bode well for its success in the growing market, as shown by the positive results of studies on its products.
Bears say
Organogenesis Holdings is a regenerative medicine company with a negative outlook based on several factors. First, their projected FY26 guidance of $350M-$420M represents a significant decline of 38%-25% year over year, with a targeted 50% decline in 1Q26. Secondly, Organogenesis faces competition from other companies in the regenerative medicine market and may struggle to gain market share. Finally, potential issues with Medicare pricing and lower-than-expected uptake of new products may also pose a risk to the company's growth and success.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares